Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer.

By I. Vergote, C. Tropé, F. Amant, G. Kristensen, T. Ehlen, N. Johnson, R. Verheijen, M. van der Burg, Á. Lacave, P. Panici and 8 more. New England Journal of Medicine, 2010

2,377 citations recorded by the source corpus.

Subfields: Oncology, Public Health, Environmental and Occupational Health, Reproductive Medicine

View Paper: https://www.semanticscholar.org/paper/d204ed0c089a8790c2d1c71e2879ec2baa2cf4a0

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. D. K. Armstrong
2. D. Jelovac

In Reproductive Medicine

1. D. K. Armstrong
2. D. Jelovac
3. Jonathan A. Ledermann
4. C. Sessa
5. D. Querleu
6. M. Mirza
7. A. González-Martín

Citations in the corpus

• Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018, positive): “A large prospective trial showed [25] that in advanced bulky stage IIIC or IV disease, three cycles of platinum-based neoadjuvant chemotherapy followed by interval debulking surgery was not inferior to primary debulking surgery followed by chemotherapy [I, A].”
• Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer (2018, neutral): “Thromboembolic event§ 2 (2) 2 (2) 7 (6) 4 (3)”
• ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease (2019, result): “In the ANTHALYA trial [196], complete resection rate (CRR) was significantly higher with additional bevacizumab compared with CRR previously reported in the EORTC study [177].”
• ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†. (2019, result): “cantly higher with additional bevacizumab compared with the CRR previously reported in the EORTC study.(177) In contrast, the GEICO 1205/NOVA trial(197) showed no benefit in the complete macroscopic”
• Recent Progress in the Diagnosis and Treatment of Ovarian Cancer (2011, result): “It also varies according to histology: it is highest in serous and lowest in mucinous EOC.”